èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã Protara Therapeutics, Inc. ã¯ããããåžå°çŸæ£ã®æ²»çã®ããã®é©æ°çãªæ²»çæ³ã®çºèŠãšæšé²ã«åãçµãã§ããŸããå瀟ã®ãªãŒãããã°ã©ã ã¯ããªã³ã管å¥åœ¢ã®æ²»çã®ããã®æ²»éšäžã®çްèçæ³ã§ãã TARA-002 ã§ãããŸããè
žäžå
šé¢é£èçŸæ£ã®æ²»çã®ããã®æ²»éšäžã®ãªã³è質åºè³ªè£å
çæ³ã§ããéèå
ã³ãªã³å¡©åç©ãéçºããŠããŸããå瀟ã¯ä»¥å㯠ArTara Therapeutics, Inc. ãšããŠç¥ãããŠããŸãããã2020 幎 5 æã« Protara Therapeutics, Inc. ã«ç€Ÿåã倿ŽããŸãããProtara Therapeutics, Inc. ã¯ãã¥ãŒãšãŒã¯å·ãã¥ãŒãšãŒã¯ã«æ¬ç€Ÿã眮ããŠããŸãã